(Q27853205)

3

0 references

Wolfgang Hartmann

object named as

Wolfgang Hartmann

16

0 references

Wolfgang E Berdel

14

object named as

Wolfgang E Berdel

0 references

author name string

Lars Henning Schmidt

1

0 references

Andreas Kümmel

2

0 references

Dennis Görlich

3

0 references

Michael Mohr

4

0 references

Sebastian Bröckling

5

0 references

Jan Henrik Mikesch

6

0 references

Inga Grünewald

7

0 references

Alessandro Marra

8

0 references

Anne M Schultheis

9

0 references

Eva Wardelmann

10

0 references

Tilmann Spieker

12

0 references

Christoph Schliemann

13

0 references

Rainer Wiewrodt

Creative Commons Attribution 4.0 International

15

0 references

language of work or name

English

0 references

publication date

2015

0 references

published in

PLOS One

0 references

volume

10

0 references

issue

8

0 references

page(s)

e0136023

0 references

copyright license

start time

27 August 2015

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Immunotherapy in the treatment of non-small cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4552388

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4552388

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4552388

CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4552388

20 March 2017

Cancer statistics, 2013

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4552388

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4552388

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4552388

PD-1 and its ligands in tolerance and immunity

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4552388

Pembrolizumab for the treatment of non-small-cell lung cancer

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4552388

Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4552388

PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4552388

PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4552388

In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4552388

Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4552388

Programmed death ligand-1 expression in non-small cell lung cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4552388

Relationship between programmed death-ligand 1 and clinicopathological characteristics in non-small cell lung cancer patients

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4552388

Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4552388

Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4552388

Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4552388

B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4552388

Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4552388

Interleukin-2 and interferon-alpha in the treatment of patients with advanced non-small-cell lung cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4552388

Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4552388

Prognostic impact of Bcl-2 depends on tumor histology and expression of MALAT-1 lncRNA in non-small-cell lung cancer.

2 June 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0136023

Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0136023

Clinical impact of programmed cell death ligand 1 expression in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0136023

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0136023

Tissue microarrays are reliable tools for the clinicopathological characterization of lung cancer tissue

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4552388

Concomitant administration of interleukin-2 plus tumor necrosis factor in advanced non-small cell lung cancer.

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4552388

[Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]

27 November 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26313362

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26313362

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-follow-up study

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26313362

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1371/JOURNAL.PONE.0136023

1 reference

2143442

ADS bibcode

2015PLoSO..1036023S

0 references

2143442

1 reference

1 reference

1 reference